抗糖尿病薬とがん:血糖値および体重管理を超えた関連性
Meng Cao1, Chu Lin1, Xiaoling Cai1
1Department of Endocrinology and Metabolism, Peking University People's Hospital, Peking University Diabetes Center, Beijing 100044, China.
Abstract:
Cancer is becoming one of the leading causes of death among patients with diabetes. Hyperglycemia and obesity, two key characteristics of type 2 diabetes, modify the risks of cancer in patients with type 2 diabetes. However, recent studies suggested that glycemic control and weight loss mediated by anti-diabetic medications might not be sufficient to lower the risks of cancer in patients with type 2 diabetes. Thus, there is a need to explore the association between anti-diabetic medications and cancer beyond glycemic and body weight control. This review has summarized the preclinical and clinical evidence between various anti-diabetic drugs and cancer. More importantly, this review focused on the underlying links between anti-diabetic medications and cancer beyond glycemic and body weight control, including modified cell proliferation, altered levels of some hormones, inflammation and oxidative stimuli, autophagy and apoptosis, intestinal flora shift, and angiogenesis and epithelial-mesenchymal transition. This review may provide insights for future clinical and mechanistic studies to further elucidate the association between anti-diabetic medications and cancer.
関連する概念動画
Oral Hypoglycemic Agents: Biguanides and Glitazones
Psychoneuroimmunology: Diabetes and Cancer
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Diabetes Mellitus: Type 2 and Gestational
Cancer Prevention
Some...


